You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國吸收合併介紹上市第一股,東陽光藥(06887.HK)今日登陸港股
格隆匯 08-07 17:26

8月7日,廣東東陽光藥業股份有限公司(以下簡稱東陽光藥,股票代碼06887.HK)登陸聯交所主板。作為首單H股吸收合併私有化加介紹上市的案例,東陽光藥通過吸收合併港股上市子公司東陽光長江藥業實現整體上市。

公開資料顯示,東陽光藥是一家從事藥物的研發、生產和商業化的綜合性製藥企業。自2003年成立以來,聚焦感染、慢病、腫瘤三大領域,擁有1100多人的研發團隊,在全球擁有150款獲批藥物,近50款在研創新藥,其中3款原創新藥獲批上市,1款即將上市,10款處於臨牀II、III期;自主申請2500多項發明專利,獲得抗感染新藥研發全國重點實驗室、中國專利金獎、廣東省科技進步一等獎等多項高水平產出和榮譽認證;創新藥HEC88473 2024年實現海外授權,甘精胰島素完成美國註冊;並且建立了覆蓋全球的銷售網絡,核心產品可威成為國內抗流感藥物第一品牌。

東陽光藥董事長張英俊在上市儀式公開致辭中表示,本次一體化的成功,公司將加速整合優質資源,快速推動創新藥管線的商業化和全球化,為可持續增長注入澎湃動能,進一步提升在全球醫藥市場的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account